Objectives To assess the cost-effectiveness of optometrist-led follow-up monitoring reviews for patients with quiescent neovascular age-related macular degeneration (nAMD) in community settings (including high street opticians) compared with ophthalmologist-led reviews in hospitals. Design A model based cost-effectiveness analysis with a 4-week time horizon, based on a ‘virtual’ non-inferiority randomised trial designed to emulate a parallel group design. Setting A virtual internet-based clinical assessment, conducted at community optometry practices, and hospital ophthalmology clinics. Participants Ophthalmologists with experience in the age-related macular degeneration service; fully qualified optometrists not participating in nAMD shared...
PURPOSE: To present a computerized model assessing individualized cost utility for current treatment...
Purpose Ophthalmologists increasingly depend on new drugs to advance their treatment options. These ...
Background: Age-related macular degeneration is the most common cause of sight impairment in the UK....
Objectives To assess the cost-effectiveness of optometrist-led follow-up monitoring reviews for pati...
ObjectivesTo assess the cost-effectiveness of optometrist-led follow-up monitoring reviews for patie...
BackgroundPatients with neovascular age-related macular degeneration (nAMD) usually attend regular r...
Background Patients with neovascular age-related macular degeneration (nAMD) usually attend regular ...
Background: Patients with neovascular age-related macular degeneration (nAMD) usually attend regular...
IntroductionStandard treatment for neovascular age-related macular degeneration (nAMD) is intravitre...
Background/aims To evaluate the cost-effectiveness of non-invasive monitoring tests to detect the on...
Objectives: To compare the ability of ophthalmologists versus optometrists to correctly classify ret...
Objectives: The aim was to quantify the direct medical cost of neovascular age-related macular degen...
Population-based studies across developed countries have estimated the prevalence rate of late age-r...
PURPOSE: To report (1) the costs of verteporfin photodynamic therapy (VPDT) in routine treatment of ...
© 2013 Dr. Robert Patrick FingerNeovascular age-related macular degeneration (nvAMD) is one of the l...
PURPOSE: To present a computerized model assessing individualized cost utility for current treatment...
Purpose Ophthalmologists increasingly depend on new drugs to advance their treatment options. These ...
Background: Age-related macular degeneration is the most common cause of sight impairment in the UK....
Objectives To assess the cost-effectiveness of optometrist-led follow-up monitoring reviews for pati...
ObjectivesTo assess the cost-effectiveness of optometrist-led follow-up monitoring reviews for patie...
BackgroundPatients with neovascular age-related macular degeneration (nAMD) usually attend regular r...
Background Patients with neovascular age-related macular degeneration (nAMD) usually attend regular ...
Background: Patients with neovascular age-related macular degeneration (nAMD) usually attend regular...
IntroductionStandard treatment for neovascular age-related macular degeneration (nAMD) is intravitre...
Background/aims To evaluate the cost-effectiveness of non-invasive monitoring tests to detect the on...
Objectives: To compare the ability of ophthalmologists versus optometrists to correctly classify ret...
Objectives: The aim was to quantify the direct medical cost of neovascular age-related macular degen...
Population-based studies across developed countries have estimated the prevalence rate of late age-r...
PURPOSE: To report (1) the costs of verteporfin photodynamic therapy (VPDT) in routine treatment of ...
© 2013 Dr. Robert Patrick FingerNeovascular age-related macular degeneration (nvAMD) is one of the l...
PURPOSE: To present a computerized model assessing individualized cost utility for current treatment...
Purpose Ophthalmologists increasingly depend on new drugs to advance their treatment options. These ...
Background: Age-related macular degeneration is the most common cause of sight impairment in the UK....